About
About Suven Life Sciences Limited
Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, develops novel therapeutics for central nervous system disorders and unmet needs in mental health in India, the United States, Europe, and internationally. It engages in the development of Masupirdine (SUVN-502), a 5-HT6 receptor antagonist for the treatment of cognitive and neuropsychiatric symptoms of Alzheimer's disease; and Samelisant (SUVN-G3031), a histamine H3 receptor inverse agonist/antagonist for the treatment of narcolepsy with or without cataplexy and idiopathic hypersomnia. The company also develops Ropanicant (SUVN-911), an a4ß2 nicotinic acetylcholine receptor (nAChR) antagonist for the treatment of major depressive disorder; Usmarapride (SUVN-D4010), a 5-HT4 receptor partial agonist for management of cognitive dysfunction; and Tenaclidine (SUVN-I6107), a muscarinic M1 positive allosteric modulator for the treatment of cognitive disorders and schizophrenia. In addition, it is involved in the development of programs, such as SUVN-M8036 Serotonin/Dopamine Modulator for psychiatric disorder indications; SUVN-D1044 5-HT4 Agonist for gastrointestinal disorders; M4 PAM for psychosis indications; P2X7 Antagonist for pain and inflammation indications; Multimodal Dual 5-HT2A Antagonist and 5-HT1A Agonist for psychosis and depression indications; 5-HT1A Agonist for treatment resistant depression; Multimodal Dual 5-HT2A Antagonist and SRI for bipolar disorders, and depression and schizophrenia; and M1 PAM for gastrointestinal disorder indications. The company was formerly known as Suven Pharmaceuticals Pvt. Ltd. and changed its name to Suven Life Sciences Limited in 2003. The company was incorporated in 1989 and is based in Hyderabad, India. Suven Life Sciences Limited operates as a subsidiary of Jasti Property and Equity Holdings Private Limited.
Visit company website
5 years, 5 months ago
Suven Life Sciences Limited is currently in a long term uptrend where the price is trading 14.3% above its 200 day moving average.
From a valuation standpoint, the stock is 938.1% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 49.7.
Suven Life Sciences Limited's total revenue sank by 45.4% to $15M since the same quarter in the previous year.
Its net income has dropped by 6.9% to $-244M since the same quarter in the previous year.
Finally, its free cash flow grew by 50.6% to $-450M since the same quarter in the previous year.
Based on the above factors, Suven Life Sciences Limited gets an overall score of 2/5.